A commercial autogenous injection vaccine protects ballan wrasse (Labrus bergylta, ascanius) against aeromonas salmonicida vapA type V by Ramirez-Paredes, J Gustavo et al.
A COMMERCIAL AUTOGENOUS INJECTION VACCINE PROTECTS BALLAN 1 
WRASSE (LABRUS BERGYLTA, ASCANIUS) AGAINST AEROMONAS 2 








, S. J Monaghan
1



















Institute of Aquaculture, Faculty of Natural Sciences, University of Stirling, Stirling, 8 
Scotland, FK9 4LA, UK 9 
2
Ridgeway Biologicals Ltd. a Ceva Santé Animale company, Units 1-3 Old Station Business 10 
Park, Compton, Berkshire, England, RG20 6NE, UK 11 
3
Centre for Environment, Fisheries and Aquaculture Science, Barrack Road - The Nothe, 12 





The Roslin Institute and Royal (Dick) School of Veterinary Studies, 15 
University of Edinburgh, Midlothian, Scotland, EH25 9RG, UK 16 
17 
*Correspondence: Professor Herve Migaud, Institute of Aquaculture, Faculty of Natural18 
Sciences, University of Stirling, Stirling, Scotland, FK9 4LA, UK 19 







Click here to view linked References
Accepted refereed manuscript of: Ramirez-Paredes JG, Verner-Jeffreys D, Papadopoulou A, Monaghan SJ, 
Smith L, Haydon D, Wallis TS, Davie A, Adams A & Migaud H (2020) A commercial autogenous injection 
vaccine protects ballan wrasse (Labrus bergylta, ascanius) against aeromonas salmonicida vapA type V. Fish 
and Shellfish Immunology, 107 (Part A), pp. 43-53. https://doi.org/10.1016/j.fsi.2020.09.040
© 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International http://creativecommons.org/licenses/by-nc-nd/4.0/
ABSTRACT 26 
Atypical Aeromonas salmonicida (aAs) and Vibrionaceae related species are bacteria 27 
routinely recovered from diseased ballan wrasse used as cleaner fish in Atlantic salmon 28 
farming. Autogenous (i.e. farm specific inactivated) multivalent vaccines formulated from 29 
these microorganisms are widely used by the industry to protect farmed wrasse despite 30 
limited experimental proof that they are primary pathogens. In this study, the components of 31 
a commercial multivalent injection vaccine containing four strains of Aeromonas salmonicida 32 
and one strain of Vibrio splendidus previously isolated from ballan wrasse in Scotland, were 33 
tested for infectivity, pathogenicity and virulence via intra peritoneal injection at pre-34 









 cfu/fish of Vibrio splendidus, V. 36 
ichthyoenteri, Aliivibrio logeii and A. salmonicida, respectively, did not cause significant 37 
mortalities, lesions or clinical signs after a period of 14 days. IP injection with both aAs and 38 
Photobacterium indicum successfully reproduced the clinical signs and internal lesions 39 
observed during natural outbreaks of the disease. Differences in virulence (LD50 at day 8-post 40 
infection of 3.6x10
6
 cfu/fish and 1.6x10
7 
cfu/fish) were observed for two aAs vapA type V 41 
isolates. In addition, the LD50 for Photobacterium indicum was 2.2x10
7 
cfu/fish. The 42 
autogenous vaccine was highly protective against the two aAs vapA type V isolates after 700-43 
degree days of immunisation. The RPSFINAL values for the first isolate were 95 and 91% at 44 
1x10
6
 cfu/fish and 1x10
7
 cfu/fish, respectively, and 79% at 1x10
7
 cfu/fish for the second 45 
isolate tested. In addition, significantly higher anti aAs seral antibodies (IgM), were detected 46 
by ELISA in vaccinated fish in contrast with control (mock vaccinated) fish. These results 47 
suggest wrasse can be effectively immunised and protected against aAs infection by injection 48 
with oil adjuvanted vaccines prepared with inactivated homologous isolates.  49 
 50 
Key Words:  wrasse vaccines, bacterial diseases, atypical Aeromonas salmonicida, cleaner 51 
fish diseases, vibriosis in wrasse, Photobacterium indicum. 52 
1- INTRODUCTION 53 
Sea lice, particularly Lepeophtheirus salmonis (Krøyer, 1837) have caused major economic 54 
losses to the Atlantic salmon industry. Parasitic infections have commonly been controlled 55 
with chemotherapeutants however alternative control methods were explored due to drug 56 
resistance. A successful alternative environmental friendly delousing approach was first 57 
tested in the Northern hemisphere in the mid-1990s where wild wrasse were deployed in 58 
salmon cages [1] including goldsinny (Ctenolabrus rupestris, L.), rock cook (Centrolabrus 59 
exoletus, L.), cuckoo wrasse (Labrus mixtus, L.), corkwing wrasse (Crenilabrus melops, L.) 60 
and ballan wrasse (Labrus bergylta, Ascanius). The latter was identified as the most desirable 61 
wrasse species as a cleaner fish for salmon mainly due to their size and delousing efficacy 62 
[2]. Ballan wrasse are distributed in-shore in rocky and algal (e.g. kelps) habitats [3] and they 63 
feed mainly on crustaceans and bryozoans, molluscs, jellyfish and other invertebrates [3]. 64 
Ballan wrasse are protogynous hermaphrodites, agastric (i.e. lacking a stomach) and 65 
physoclistic (i.e. closed swim bladder) hence they cannot rapidly regulate the gas pressure in 66 
the swim bladder [3]. Farmed ballan wrasse are currently being used for delousing salmon in 67 
sea cage sites, however, disease outbreaks in hatcheries and post-deployment in salmon pens 68 
are critical bottlenecks for the industry.  69 
Bacterial pathogens are considered the major cause of infectious diseases and mortalities in 70 
farmed ballan wrasse produced for sea lice control in the salmon farming industry [3-5]. In 71 
Scotland, atypical Aeromonas salmonicida (aAs) vapA type V and VI, Vibrio splendidus, V. 72 
ichthyoenteri, Aliivibrio salmonicida, A. logeii, and Photobacterium indicum are the bacterial 73 
pathogens most frequently isolated from ballan wrasse during outbreaks of disease in both 74 
hatcheries and post deployment in salmon sea sites [6]. Similar reports are available for the 75 
species in Norway [5].  76 
Immunisation of farmed salmonids (Atlantic salmon and rainbow trout) against typical As 77 
using fully licenced oil-adjuvanted injectable vaccines has historically proven successful and 78 
is a standard practice [7]. However, immunisation of non–salmonid species against typical 79 
and atypical As has been rather challenging [8-10]. For instance, an experimental vaccine 80 
containing atypical strains protected Arctic charr (Salvelinus alpinus, L.) but not in European 81 
grayling (Thymallus thymallus, L.) [11]. Furthermore, commercial furunculosis vaccines for 82 
salmonids have induced protection in Atlantic halibut (Hippoglossus hippoglossus, L.) but 83 
not in Atlantic cod (Gadus morhua, L.) or turbot (Scophthalmus maximus, L.) [8-10]. 84 
Currently no licenced or registered vaccines are commercially available in the UK for the 85 
prevention and control of infectious diseases in ballan wrasse. Therefore, prophylactic 86 
treatments in Scotland are mainly based on the use of autogenous vaccines, which are 87 
formulated with antigens derived from pathogens recovered during episodes of elevated 88 
mortality [3]. 89 
Autogenous or “herd specific” vaccines are farm specific immunological veterinary 90 
medicinal products that have the potential to be rapidly developed and deployed when no off-91 
the shelf fully licensed vaccines exist or these have proven infective. In principle, autogenous 92 
vaccines must be inactivated (killed), manufactured in licenced facilities, used only under 93 
veterinary prescription and on the sites where the pathogens were isolated [12, 13].  94 
In Scotland, autogenous vaccines for ballan wrasse were first developed from isolates 95 
collected during disease outbreaks between 2013 and 2014 (Ridgeway Biologicals Ltd.) and 96 
used in hatcheries and wild caught wrasse. The vaccine formulation later evolved and new 97 
isolates were introduced following a health screening surveys [6]. However without 98 
established challenge model for the Scottish bacteria and wrasse populations, the actual 99 
virulence of the isolates and the efficacy/potency of the vaccine components remained 100 
unknown.  101 
Overall, i.p. injection challenges with atypical strains of As have been successful in several 102 
species with a wide range of doses used [14]. For instance, juvenile spotted wolfish 103 




cfu / 104 
mL [10, 15], while high morbidities in turbot were reported [16], but only in fish exposed 105 




 cfu / mL. Experimentally infected ballan wrasse and 106 
lumpsucker also experienced high morbidities (> 70%) when challenged with Norwegian aAs 107 
isolates at doses of 2 x10
3
 cfu / mL (bath) and 2 x 10
6
 cfu /mL (i.p. injection), and 10
8
 cfu 108 
/mL (i.p. injection), respectively [17, 18]. As for the Vibrionaceae pathogens in cleaner fish, 109 
in a previous study in Norway, only Vibrio anguillarum originally isolated from Atlantic 110 
salmon caused high mortalities (up to 60%) in ballan wrasse under experimental conditions, 111 
while Norwegian ballan wrasse isolates of the same bacterial species caused < 20% 112 
mortalities when challenged via bath, cohabitation and i.p. injection [17].  113 
Given that, aAs and Vibrionaceae isolates are highly heterogenic and variable, and virulence 114 
is often strain and host dependant [4, 19], the establishment of similar experiments in other 115 
geographical areas such as Scotland is of high relevance for the local industry.  116 
The objective of the present study was to develop in vivo challenge models via intraperitoneal 117 
(i.p.) injection in Scottish ballan wrasse (25-50 g) to investigate the infectivity, pathogenicity 118 
and virulence of bacterial isolates routinely recovered from diseased wrasse and used as 119 
antigens in commercial autogenous vaccines. These isolates included aAs vapA types V and 120 
VI, Vibrio splendidus, V. ichthyoenteri, Aliivibrio salmonicida, A. logeii, and Photobacterium 121 
indicum. Furthermore, we aimed to assess survival rates in vaccinated and control fish which 122 
have been experimentally infected and vaccine potency expressed as relative percent 123 
survivals (RPS). Specific antibody (IgM) kinetics were also assessed in vaccinated fish. 124 
 125 
2- MATERIALS AND METHODS 126 
2.1 Bacterial identification and genotyping  127 
The bacterial isolates used were recovered from diseased fish at commercial hatcheries and 128 
characterised on the basis of phenotypic and genotypic characteristics as part of a previous 129 
study [6]. In brief, bacterial DNA was extracted using Genesig® Easy DNA/RNA Extraction 130 
Kit (Primerdesign Ltd, Southampton UK) according to the manufacturer’s instructions. 131 
Species confirmation was performed on the samples by targeting the V3-V4 hypervariable 132 
region of the 16S rRNA gene [20] and the subunit B protein of DNA gyrase (topoisomerase 133 
type II) – gyrB gene [21]. The Aeromonas salmonicida isolates were then genotyped by 134 
sequencing the A-layer membrane as described previously [22].  135 
For the experimental infections, the aAs isolates were grown on tryptone soya agar (TSA, 136 
Oxoid, UK) or blood agar (BA; TSA + 5% sheep blood Thermo Fisher) while the 137 
Vibrionaceae isolates were on sea water agar (SWA, Oxoid, UK) and incubated at 22 °C for 138 
48 and 24 h, respectively. For growth in liquid media, aAs isolates were inoculated onto 139 
trypticase soy broth (TSB, Oxoid, UK) and Vibrionaceae isolates onto TSB + 2% NaCl 140 
(Oxoid, UK,) and incubated at 22 °C for 18-24 h, with continuous shaking at 180 rpm. For 141 
harvesting, all bacteria were centrifuged at 4 °C for 10 min at 2,000 x g, bacterial pellets were 142 
then washed with sterile 1x phosphate-buffered saline (PBS) and resuspended in sterile PBS 143 
to the required concentration (cfu/mL) for the experiments.  144 
With the exception of isolate TW164/15 (aAs vapA type VI) that was recovered from 145 
moribund lumpsucker (Cyclopterus lumpus) the rest of the isolates were recovered from 146 
ballan wrasse. A summary of the isolates used in this study is presented in Table 1.  147 
 148 
2.2 Experimental fish 149 
A population of naïve i.e. unvaccinated and non-diseased ballan wrasse (30 ± 5 g) was 150 
provided by a commercial cleaner fish hatchery on the west coast of Scotland. Prior to the 151 
study, the health status of the fish was checked by screening a subset of the population with 152 
standard histological, bacteriological and molecular methods to confirm the absence of aAs 153 
[6, 22], amoebic gill disease [23] and Vibrionaceae related bacteria [20, 21]. After 154 
confirming they were free of these pathogens, fish were transferred to the Centre for 155 
Environment, Fisheries and Aquaculture Science (Cefas) Weymouth Laboratory in February 156 
2017.   157 
Fish were acclimated and quarantined for 3 weeks after arrival in 6 aerated aquaria (approx. 158 
900 L, tanks enriched with artificial plastic kelp and sections of plastic pipes to provide hides 159 
to the fish) at 12.0 ± 0.5 °C with a 20:4 h light:dark photoperiod, water flow of 4.0 L / min, 160 
salinity 34 ± 2 ‰,  dissolved oxygen (DO) at 8 ± 0.5 mg / L and pH 7.8 ± 0.4. During this 161 
period, fish were further screened for bacteriology (swabs from head kidney plated onto 162 
SWA), histopathology (fixed in 10% neutral buffered formalin) and molecular methods as 163 
described before. In addition, virology diagnostic tests were performed to discard the 164 
presence of notifiable viral diseases as per the protocols in the OIE manual of diagnostic tests 165 
for aquatic animals [24]. 166 
 167 
2.3 Vaccine  168 
A commercial (oil-based, inactivated) multivalent autogenous (emergency) vaccine, 169 
containing aAs isolates TW3/14, TW4/14, TW187/14, TW164/15 and Vibrio splendidus 170 
isolate TW130/16 (Table 1) previously isolated from ballan wrasse [6] was provided by 171 
Ridgeway Biologicals Ltd. The vaccine was shipped to Cefas and stored at 4 ± 1 °C prior to 172 
use. 173 
 174 
2.4 Confirmation of infectivity of components of multivalent autogenous vaccine 175 
The virulence of bacterial isolates, representative of strains commonly used as components of 176 
the multivalent autogenous vaccines used in the industry, was assessed in a series of infection 177 
experiments performed in 30 L tanks enriched as for acclimation tanks (Table 2). For all the 178 
infection experiments, fish were transferred from a stock tank, anaesthetised with MS-222 179 





cfu/fish) of the relevant bacterial suspension. Where included, control fish were injected with 181 
100 µL of sterile PBS. Fish were then allocated to respective 30 L aquaria each with water 182 
flow of 0.6 – 1.0 L / min, all other parameters remained the same as described above. Fish 183 
were observed at least twice a day for signs of disease for 7-14 days. The pathogens that 184 
caused mortalities, were recovered from the diseased fish, purified and stored at -80 °C. 185 
For the first infection experiment, limited numbers of 30 ± 5 g fish (n= 6) were injected with 186 
an OD600 ~1.57 bacterial suspension of different isolates representing 4 different bacterial 187 
species (aAs including two type V and one type VI isolates, Vibrio splendidus, Aliivibrio 188 
salmonicida and Vibrio ichthyoenteri) (Table 2).  189 
In the second infection experiment, the pathogens that did not cause morbidities or signs of 190 
disease during the first infection experiment were i.p. injected in naïve ballan wrasse at  191 
higher doses (3 – 8 x 10
9
 cfu/fish; Table 2). To confirm that these isolates were not 192 
pathogenic via this exposure route, the number of fish tested was also increased to 15 per 193 
isolate, and the length of the experiment was prolonged to 16 days. In addition, an aAs vapA 194 
type VI (isolate TW164/15) recovered from lumpsucker was also included (Table 2). 195 
In the third infection experiment, fish (n= 12) were i.p. injected with medium (10
7
 cfu/fish) 196 
and high (10
9
 cfu/fish) doses of 2x isolates of Aliivibrio logei and Photobacterium indicum as 197 
well 2x isolates of aAs vapA type VI and observed for at least 25 days (Table 2). The isolates 198 
used were prepared directly from cryopreserved stocks and had not previously passaged in 199 
fish.  200 
Moribund fish and mortalities from all experiments were removed from the tanks, their 201 
external and internal condition assessed. Head kidney swabs were taken onto solid media for 202 
bacteriological assessment. Isolates not recovered, despite being i.p injected into the fish at 203 
high doses, were regarded as non-infectious. The bacteria recovered were subcultured to 204 
purity, their identities confirmed and cryopreserved at – 80 °C until further use.    205 
Comment [MOU1]: Moved from 
bottom of section 
Additional infection experiments 4 and 5 were also undertaken. These were to better 206 
determine both the relevant virulence of the different aAs isolates vapA type V and identify 207 
doses that would ideally result in high, but not excessive (50-75% mortality), suitable for use 208 
in vaccine efficacy testing. In infection experiment 4, 4x different doses of each pathogen 209 
were tested (n= 15 fish per dose) with a control treatment (PBS) included. Initial results 210 
generated by infection experiment 4 were confirmed in a second set of pre-tests with a longer 211 
observation period post injection (4 weeks) without PBS controls (Table 2). The isolates used 212 
were passaged (recovered from moribund fish) from infection experiments 1 and 2 (Table 2). 213 
For the isolates where the use of lower and higher doses caused a mortality response below 214 
and above 50% respectively, the median lethal dose (LD50) was calculated according to [25] 215 
to define and compare their virulence at the time point of occurrence. Results obtained from 216 
both experiments 4 and 5 were used to select isolates for vaccine testing and determine the 217 
doses for the main challenge infection in the vaccine efficacy trial (Table 2). In addition, 218 
differences within the aAs vapA type V isolates TW4/14, TW187/14 and TW3/14 were 219 
investigated with macrorestriction analysis using pulsed field gel electrophoresis (PFGE) as 220 
described previously [26] with the following modifications. Bacteria were grown on TSA at 221 
15 °C for 72 – 96 h, SpeI restriction enzyme (5U per 150 µL, New England Biolabs) was 222 
used [27] and the electrophoresis conditions comprised switch times of 2 – 6 s at 15 °C and 223 
200 V for 37 h. 224 
 225 
2.5 Vaccination  226 
Two groups of 150 fish were tagged and i.p. injected with 0.05 mL of either the test vaccine 227 
or sterile PBS (control group / mock vaccinated). For this, fish were randomly transferred 228 
from their stock tank with a net into a bucket containing tank water at 12 ± 2 °C. Thereafter, 229 
groups of 2-5 fish were transferred at a time to a further bucket with MS-222 for anaesthesia 230 
and tagging. On a clean worktable each fish was marked using the Visible Implant Elastomer 231 
tagging system (VIE, Northwest marine technology, Inc). Mark colour was determined as 232 
orange for mock vaccinated and blue for the vaccinated fish (Figure 1). 233 
Immediately after tagging each fish was injected with the appropriate treatment using an 234 
automatic gun for the group of vaccinates and a sterile syringe for the mock vaccinates. For 235 
this, fish were i.p. vaccinated through the ventral wall of the coelomic cavity, one pelvic fin 236 
length anterior to the pelvic girdle and transferred directly into their holding tank at 12 ± 0.5 237 
°C to recover (Figure 1). Vaccinated fish were then divided into 4 tanks (300 L with artificial 238 
plastic kelp and sections of plastic pipes to provide hides to the fish), 2 containing 75 fish 239 
vaccinated fish each and 2 tanks containing 75 control (mock vaccinated) fish each.  240 
Fish were held for 65 days at 12 ± 0.5 °C (780 DD) and blood samples collected from the 241 
caudal vein on days 31 and 65 post vaccination (prior to challenge) from 15 fish of each tank. 242 
The blood samples were centrifuged immediately after collection at 3,000 x g for 10 min and 243 
serum kept at -20 °C until used for serological analyses.  244 
 245 
2.6 Vaccine efficacy testing 246 
After the immunisation period was completed, vaccinated and control fish (mock vaccinated) 247 
were challenged with the two most virulent strains i.e. TW4/14 (aAs vapA type V) and 248 
TW3/14 (aAs vapA type V) using a tag and mix model with two different doses (pseudo 249 
replicate tanks), here referred as medium and high for isolate TW4/14 and high and very high 250 
for isolate TW3/14  as detailed in Table 3. 251 
 252 
2.7 Infection and vaccination experiments: observations and sampling   253 
For all the infection experiments, fish were observed at least twice a day. Diseased fish were 254 
classified as moribund or near moribund (humane endpoints) based on clinical signs 255 
(typically extreme lethargy when approached with a hand net). They were then euthanised by 256 
overdose of anaesthetic followed by confirmation of death by brain destruction, a UK 257 
Animals (Scientific Procedures) Act 1986 Amended Regulations (SI 2012/3039) Schedule 1 258 
approved method (S1-M).  All euthanised and dead fish were recorded throughout the 259 
experiments and accounted for posterior statistical analyses. To confirm specific mortalities, 260 
all moribund fish were necropsied, checked for gross pathology and sampled for bacteriology 261 
and histopathology as previously described. The challenge experiments were typically 262 
concluded when there was a period of at least five days with no mortalities. At the end of the 263 
vaccine efficacy trial, all surviving fish were killed by S1‐ M and blood sampled and 264 
processed as described before to measure specific antibody levels in the serum by ELISA. 265 
All the experimental infections and vaccine efficacy tests were performed at 15 °C. Water 266 
temperatures were gradually increased over an acclimation period of 5-7 days prior to 267 
challenge. 268 
 269 
2.8 Specific IgM response  270 
An indirect enzyme‐ linked immunosorbent assay (ELISA) was developed to detect and 271 
estimate the levels of specific anti-aAs IgM in the ballan wrasse sera pre-vaccination and 272 
when the immunisation period was completed. Six samples including 2 replicates from each 273 
group were used for assessment of specific antibody responses by ELISA.  274 
Antibody titres were determined according to the protocols outlined by [28] with 275 
modifications. Briefly, 96 – well ELISA plates (Immulon 4HBX, Thermo Scientific) were 276 
coated with 50 μL of 0.05% w/v poly – L– lysine in carbonate – bicarbonate buffer (0.05 M 277 
carbonate-bicarbonate pH 7.4, Sigma-Aldrich, St.Louis, UK) and incubated for 60 min at 278 
room temperature (RT). Plates were then washed 2 times with a low salt wash buffer (LSWB) 279 
(0.02 M Trizma base, 0.38 M NaCl, 0.05% Tween-20, pH 7.3). Bacteria i.e. aAs type V 280 
isolate TW4/14, 100 μL at 10
8
 cfu/mL (OD600 1.0), were then added to each well and plates 281 
were incubated overnight at 4 °C. The bacteria were previously prepared by growing them on 282 
TSB at 22 °C for 48 h with continuous shaking at 150 rpm and washed 2 times with PBS, 283 
resuspended and adjusted to an OD600 1.0 prior to 96 – well plates inoculation. 284 
Glutaraldehyde (50 μL, 0.05% (v/v)) diluted in PBS was added to the wells of the ELISA 285 
plate to fix the antigen, incubated 20 min at RT and plates were washed 3 times with LSWB.  286 
The plates were then post-coated with 3% w/v casein in distilled water (250 μL) to block non-287 
specific binding sites and incubated for 180 min at RT. The supernatant was decanted and 288 
plates were stored at -20 °C for up to 3 weeks. LSWB was used to wash the plate 3 times and 289 
100 μL of hydrogen peroxide (H2O2; 0.3% of 10% stock solution in 10% methanol) was 290 
added to each well to quench endogenous peroxidase activity of the bacteria and incubated 291 
for 30 min at RT.  292 
Diluted serum (100 μL per well; from 1:50 to 1:800) in 0.5% casein (w/v) and in PBS, were 293 
added to the plates and incubated for 1 h at RT.  Plates were washed 5 times with high salt 294 
wash buffer (HSWB) (0.02 M Trizma base, 0.5 M NaCl, 0.1% Tween-20, pH 7.4) and were 295 
incubated with the last HSWB wash for 5 min at RT.   296 
Anti – Asian sea bass IgM MAbs (ADL, Stirling, UK) (shown to cross react with ballan 297 
wrasse IgM) diluted 1/50 with 0.01% Bovine Serum Albumin (BSA) in PBS was then added 298 
to each well (100 μL), and incubated for 1 h at RT. The plates were then washed 5 times in 299 
HSWB as described above. Goat anti – mouse – horseradish peroxidase (HRP) conjugate 300 
(Sigma-Aldrich, UK) diluted 1/4000 with 0.01% BSA in LSWB was then added to the plates. 301 
Chromogen in substrate buffer (prepared by adding 150 μL of chromogen 42 mM trimethyl-302 
benzidine, TMB to 15 mL of substrate buffer containing 5 μL H2O2 in 6 mL of 50% acetic 303 
acid) was then added (100 μL / well) for assay development.  304 
The plates were incubated for 3 – 5 min at RT and the reaction stopped by adding 50μL 305 
sulfuric acid (2 M H2SO4). The absorbance was measured at OD450 using a 96 – well plate 306 
spectrophotometer (Biotek Instruments, Friedrichshall, Germany). The sensitivity threshold 307 
of the assay was determined as 3x the absorbance value of wells containing PBS (background 308 
absorbance). Samples above this value were considered positive for specific antibodies. 309 
 310 
2.9 Statistical analyses 311 
The efficacy/potency of the vaccine was assessed by calculating the relative percent survival 312 
(RPS) which indicates the proportional percentage between the cumulative (cm) morbidities 313 
of vaccinated group and cumulative morbidities of mock vaccinated group using the equation 314 
below [29]. 315 
         
                             
                                 
        
Minitab 18 was used to produce Kaplan – Meier survival curves and perform log-rank non-316 
parametric tests (significance level p < 0.05) for survival comparisons. Antibody responses in 317 
serum samples of vaccinated and non – vaccinated ballan wrasse were tested for normality 318 
(Anderson-Darling test) and homogeneity of variance (Levene’s test). Kruskal-Wallis non – 319 
parametric test was used for dose response assessment in relation to antibody titres while a 320 
pairwise comparison (Mann Whitney-U test (CI = 95%) was conducted between the antibody 321 
responses. 322 
 323 
2.20 Ethical statement  324 
Bacterial infection and vaccination procedures were performed under the authority of UK 325 
Government Home Office project licences, following approval by the Animal Welfare and 326 
Ethical Review Body (AWERB) at the Centre for Environment, Fisheries and Aquaculture 327 
Science (Cefas) and University of Stirling. Ballan wrasse were treated in accordance with the 328 
Animals (Scientific Procedures) Act 1986 Amended Regulations (SI 2012/3039). 329 
 330 
3- RESULTS 331 
3.1 Infection experiments 332 
In the first two infection experiments, injection with high doses of aAs type V isolates 333 
TW3/14, TW4/14 and TW187/14 and type VI isolate TW164/15 resulted in 100% 334 
moribundity/mortality by 7 days post challenge (Table 2). Clinical signs were first recorded 335 
at 4 days post infection (dpi) for both vapA types and 100% morbidities achieved by 4 and 8 336 
dpi, for vapA types V and VI respectively. In all experiments, the aAs isolates were recovered 337 
from moribund fish as pure cultures (punctate whitish to greyish colonies) from swabbed 338 
internal organs. The aAs type VI isolate tested produced a diffusible pigment, (brown on TSA 339 
and grey on BA) that became more evident after five days incubation (Supplementary File1). 340 
A representative isolate from each strain was stored at -80 °C under Cefas bacterial culture 341 
collection codes 17032, 17033 and 17034 after being in vivo passaged in fish.  342 
The infections performed with Aliivibrio salmonicida, Allivibrio logei, Vibrio splendidus and 343 
Vibrio ichtyoenteri did not cause any sign of disease or mortalities after 7 dpi in infection 344 
experiment 1 (Table 2). In infection experiment 2, only Aliivibrio salmonicida caused 2 345 
mortalities (13%) on day 3 and the other three were not pathogenic.  346 
In infection experiment 3 (Table 2), fish infected with a medium dose of aAs vapA type VI 347 
isolates TW184/16 (1.6x10
7
 cfu/fish) and TW164/15 (3x10
7
 cfu/fish) resulted in mortalities 348 
of 25% and 33% respectively, while a high dose (10
9
 cfu/fish) caused 100% mortalities for 349 
both isolates. The two aAs type VI isolates presented brown pigment as described before. 350 
Signs of disease presented more rapidly for isolate TW184/16 for medium (6 dpi) and high (2 351 
dpi) dose but similar to those of TW164/15 (7 and 3 dpi, respectively) (Supplementary File 352 
2). Morbid fish showed some signs of reduced appetite often followed by imbalance, lethargy 353 
and full loss of equilibrium. Gross external pathology included ascites, and occasionally 354 
haemorrhaging at the injection site, internally liquefaction of organs and white deposits in the 355 
peritoneum (Supplementary File 3). More liquefaction was noted with TW184/16 than 356 
TW164/16. Interestingly the bacterium was not isolated from any survivor fish challenged 357 
with medium dose at termination on 14 (TW184/16) and 16 (TW164/15) dpi and there were 358 
no any obvious external or internal signs of disease in them. 359 
The Photobacterium indicum isolates TW138/16 and TW181/16 both caused 11 (92%) 360 




 cfu/fish 361 
respectively. The remaining fish injected with a high dose of TW138/16 was removed on day 362 
3 post infection while the last fish injected with TW181/16 were euthanised on welfare 363 
grounds at day 6 post infection (Supplementary File 4). For the Photobacterium indicum 364 




 cfu/fish), of isolates TW181/16 and 365 
TW138/16 resulted in 8/12 and 6/12 mortalities respectively by day 3 post challenge 366 
(Supplementary File 4). The remaining fish (n= 4) in the tank challenged with TW181/16 367 
were terminated at day 9 post infection as no morbidities occurred for 3 days and all 368 
presented lesions at the injection site during the daily observations. In the tank infected with 369 
medium dose of isolate TW138/16 a single dead fish with a large lesion around the injection 370 
site was removed on day 9, while monitoring of the remaining fish (n= 6) continued. On day 371 
16 post infection all surviving fish (n=6) presented severe ventral lesions at the i.p. injection 372 
site (Supplementary File 5) and some of these lesions extended into the cavity and for this 373 
reason the experiment was terminated. Morbid fish infected with Photobacterium indicum 374 
showed a reduced feeding response often followed by imbalance, lethargy and full loss of 375 
equilibrium with a very rapid progression (< 24 h) of the signs. During the necropsies, the 376 
majority of the fish had ascites, liquefaction of organs and swelling coelomic cavity due to 377 
ascites. Internally, haemorrhages or lesions were noted and the severity of these progressed 378 
over time. 379 
Additional testing of isolate aAs type V (TW4/14) in infection experiments 4 and 5 confirmed 380 
this organism was virulent. Morbidities were recorded within 2 dpi with the high dose (10
8
 381 
cfu/fish) and 100% mortalities were reached by day 4. A dose of 10
7
 cfu/fish reached a 382 
maximum of 87% mortality by day 6 post infection, while no signs of disease or morbidities 383 
were noted for fish challenged with the lowest dose (10
4
 cfu/fish) (Supplementary File 6). 384 
Similar results were obtained in the second pre-test, with 53% for group exposed to 10
6
 385 
cfu/fish and only 7% in the group exposed to 10
4
 cfu/fish. (Supplementary File 7). The 386 
predicted LD60 based on these experiments was between 10
6
 cfu/fish (53%) and 10
7
 cfu/fish 387 
(87%), with 10
7
 cfu/fish selected as one of the doses for the vaccine efficacy trials.  388 
For the additional testing undertaken with aAs type VI (TW164/15) in infection experiment 4, 389 
only a single morbidity occurred at 3 dpi, while the rest of the fish showed no visual signs of 390 
disease or adverse behaviour. The trial was terminated at 20 dpi and fish (n= 6) sampled for 391 
bacteriology. All inoculated plates were considered negative as no significant bacterial 392 
colonies were observed. For these reasons this isolate was not used for the vaccine testing and 393 
a replacement isolates was selected as described below. 394 
 395 
3.2 Virulence determination  396 
LD50 values for the different isolates by day 8 post infection were calculated based on results 397 
from all the infection experiments.  Atypical Aeromonas salmonicida vapA type V isolate 398 
TW4/14 was the most virulent followed by aAs vapA type V isolate TW3/14, Photobacterium 399 
indicum and aAs vapA type VI. The aAs vapA type V isolates (TW3/14, TW4/14 and 400 
TW187/14) were chosen for macrorestriction analysis using PFGE to select a replacement 401 
isolate for aAs vapA type VI (TW164/15) which was not virulent during experiment 3. 402 
Differences were observed in the restriction sites for isolate TW3/14 in comparison to 403 
TW4/14 and TW187/14 (Figure 2) which may explain the differences in virulence mentioned 404 
above. The Aliivibrio logei, Vibrio splendidus, Aliivibrio salmonicida and Vibrio ichtyoenteri 405 
were not pathogenic. The average of the 3 estimations for aAs vapA type V (TW4/14) was 406 
3.6x10
6
 cfu/fish. The average of the 2 estimations for Photobacterium indicum was 2.2x10
7 407 
cfu/fish. A comparison of all the LD50 values of the different isolates is presented in Table 4. 408 
 409 
3.3 Vaccine efficacy 410 
Significant protection was demonstrated with vaccinated fish experiencing significantly 411 
lower mortalities than control fish when challenged with aAs type V from isolates TW4/14 412 
and TW3/14. First morbidities were recorded at 5 dpi (TW3/14) and 6 dpi (TW4/14) in the 413 
mock-vaccinated groups, and 7 dpi (TW3/14) and 15 dpi (TW4/14) in the vaccinated groups 414 
(Figure 3A, B).  415 
Mortalities were significantly higher for mock-vaccinated fish challenged with either of the 416 
two isolates over a period of 24 days (Figure 3A, B). Isolate TW3/14 at a very high dose of 417 
1x10
8
 cfu/fish resulted in 96% mortality relative to the control fish and 34% mortality relative 418 
to the vaccinated group. With the same isolate, a dose of 10
7
 cfu/fish caused 84% mortality 419 
relative to the control groups and only 18% relative to the vaccinated group. Isolate TW4/14, 420 
at a high dose of 10
7
 cfu/fish, caused 100% mortalities relative to the control and only 9% 421 
relative to the vaccinated group while a medium dose of 10
6
 cfu/fish caused 44% in the 422 
control groups and only 2% to the vaccinated fish.  423 
The RPS values in the ballan wrasse challenged with isolate TW4/14 at medium and high 424 
doses were 95% (10
6
 cfu/fish) and 91% (10
7
 cfu/fish), respectively. The group exposed to 425 
strain TW3/14 had an RPS of 79% with the high dose of 10
7
 cfu/fish but a low RPS (20%) 426 
was recorded for the group injected with the very high challenge dose (10
8
 cfu/fish) (Table 427 
4). Despite the low RPS, the survival of vaccinated fish in this group was still significantly 428 
higher when compared with the mock vaccinated group (Figure 3B). 429 
 430 
3.4 Specific IgM response 431 
Non – specific binding was observed in the preliminary results (Supplementary File 8). This 432 
was reduced when plates were treated with 0.3% hydrogen peroxide to quench endogenous 433 
peroxidase activity of the bacteria and when 0.5% casein and 0.01% BSA were included in 434 
the fish serum and Anti – Asian sea bass IgM MAbs, respectively.  435 
A very weak antibody response was noted for serum samples collected from mock-vaccinated 436 
fish (controls) prior to challenge and these were considered negative. The vaccinated fish had 437 
significantly higher mean antibody titres at all sera dilutions in contrast to mock-vaccinated 438 
fish (Figure 4).  439 
4- DISCUSSION  440 
In the present study, the virulence of aAs type V and VI, Aliivibrio logei, Aliivibrio 441 
salmonicida, Vibrio splendidus, Vibrio ichthyoenteri and Photobacterium indicum were 442 
assessed. The results obtained confirmed that aAs vapA type V was the most pathogenic of all 443 
the bacterial species (followed by Photobacterium indicum, aAs VI and the rest of the 444 
Vibrionaceae). Importantly, the vaccine tested was highly protective against aAs type V and 445 
significantly higher titres of specific systemic IgM were detected in vaccinated fish when 446 
compared to controls. 447 
The virulence studies confirmed that aAs vapA type V (from both isolates tested) were highly 448 
virulent in ballan wrasse when i.p. injected. The RPS obtained with medium and high doses 449 
for vapA type V from isolate TW4/14 (95% and 91%, respectively) and high dose of vapA 450 
type V from isolate TW3/14 (79%) strains, confirmed the effectiveness of the injection 451 
vaccine against homologous strains of aAs and were in agreement with previous results 452 
conforming that ballan wrasse can be effectively immunised by i.p. injection against this 453 
pathogen [17]. When vaccinated ballan wrasse were challenged with a very high dose (10
8
 454 
cfu/fish) of the strain TW3/14, RPS was only of 20% suggesting that high challenge dose 455 
may have suppressed or overwhelmed protective memory responses. This highlights the 456 
relevance of biosecurity and good farming practices to maintain the pathogen challenge 457 
pressure as low as possible during the production cycle.   458 
A specific antibody response (IgM) to the vaccine was measured in vaccinated fish at 780 459 
DD which was significantly higher compared to non-vaccinated fish. The high RPS levels in 460 
vaccinated fish and specific antibody response following vaccination are indicators that the 461 
vaccine indeed triggered a specific protective humoral response against aAs. Similar 462 
responses have been induced in other species immunised with typical or atypical stains of As, 463 
such as lumpsucker [30, 31], Atlantic salmon [32, 33], rainbow trout [34] and spotted wolfish 464 
[35]. A high quantity of cytoplasmic peroxidases (e.g. thiol peroxidase) have previously been 465 
reported in A. salmonicida cells [36] and high antigen endogenous peroxidase activity 466 
appeared to cause substantial background during ELISA development. This background was 467 
quenched using hydrogen peroxide prior to antibody-antigen complexing. However, a high 468 
absorbance threshold of the ELISA could not be avoided using our cut-off criteria (3x 469 
background OD = 0.4), thus a 1/50 test titre was the most preferable to use to determine 470 
positive antibody responses to aAs vaccination. Nonetheless, the titre of antibodies was 471 
consistently higher in vaccinated fish up to and including a dilution of 1/800. These results 472 
suggested that antibodies might be involved in protection against aAs. 473 
Interestingly, differences in virulence were observed for two atypical Aeromonas salmonicida 474 
vapA type V isolates (TW3/14 and TW4/14), with the latter being the most virulent. 475 
Microrestriction and PFGE analysis corroborated these results, indicating small but 476 
potentially important genomic differences between isolates. Atypical Aeromonas salmonicida 477 
isolates  heterogeneity has been previously assessed with the same method [27]. 478 
Characterisation of all the available aAs vapA types for ballan wrasse by PFGE will be 479 
beneficial to select isolates for future vaccine formulations.   480 
The  atypical Aeromonas salmonicida vapA VI isolates appeared less virulent than type V and 481 
similar results were reported for Norwegian aAs type V and VI isolates [17]. In that study aAs 482 
type V induced high mortalities (75 – 89% morbidities) in 50 g ballan wrasse when i.p. 483 
injected with 10
7
 cfu /fish and also by cohabitation (51%). The type VI isolates were less 484 
virulent, in particular by cohabitation (8%) than i.p. injection (70 – 85%). In previous reports 485 
lumpsucker succumbed to disease at lower doses of 2 x10
3
 cfu/mL (bath) and 4 x 10
4
 cfu 486 
/fish (i.p. injection) after exposure [18]. Other fish species like spotted wolfish also 487 




cfu / mL) by i.p. injection 488 




 cfu / mL) for mortalities to 489 
be induced by i.p. injection [16]. As suggested previously, there is a strong association 490 
between host species and vapA type and it is possible that vapA type V is more strongly 491 
associated with wrasse than lumpfish and vice versa for type IV [37]. Interestingly, in the 492 
present study, survivor fish infected with aAs type VI at a medium dose (10
7
 cfu / fish) did 493 
not show any obvious external or internal signs of the disease and no bacteria were recovered 494 
from those fish, suggesting that ballan wrasse were able to clear the infection. This is in 495 
agreement with a previous study that reported similar responses in survivors from groups 496 
infected with aAs type V and VI [17].  497 
The aAs vapA type VI isolates occasionally displayed a peculiar alternative morphology that 498 
included the presence of large greyish and small transparent colonies (Supplementary File 9). 499 
Previous reports have documented this phenomenon associated with variable expression of a 500 
functional A-layer and consequently with variable virulence [22, 38-42]. Although in the 501 
present study, the inclusion of isolates displaying such alternative morphology was generally 502 
avoided, this should not be ruled out as a possible explanation behind the lack of virulence 503 
observed in this experiment.  504 
This study is also the first experimental confirmation that Photobacterium indicum can be 505 
pathogenic towards wrasse, through fulfilment of Koch’s postulates.  Photobacterium 506 
indicum was regularly isolated from diseased ballan wrasse during disease surveys in 507 
Scotland and it was linked to histopathological lesions[6]. There are no previous reports on 508 
fish susceptibility to Photobacterium indicum although it has been isolated from moribund 509 
American lobster (Homarus americanus) associated with stress and has been reported as an 510 
opportunistic pathogen for this crustacean species [43, 44]. In cleaner fish, Photobacterium 511 
sp. was recently recovered from lumpsucker experiencing mortalities due to Pseudomonas 512 
anguilliseptica under rearing conditions in Scotland [45]. The pathogenicity results for 513 
Photobacterium indicum obtained in the present study need to be treated with caution as 514 
disease was induced only via i.p. injection which bypasses the natural protective mucosal 515 
barriers of the host e.g. skin, gills and gastrointestinal tract [46, 47]. Signs of disease and 516 
gross pathology for Photobacterium indicum were similar to those seen with aAs with 517 
moribund fish showing reduced feeding response often followed by imbalance, lethargy and 518 
full loss of equilibrium. The peritoneal cavity of the diseased fish was extended (ascites) and 519 
internally, liquefaction was observed in all the organs. Granulomatous formations were seen 520 
in livers of moribund fish infected with aAs which concurred with previous reports [17]. This 521 
needs to be considered when performing differential diagnosis based on gross pathology and 522 
clinical signs. Ventral lesions at the i.p. injection site were observed on survivor fish, which 523 
may be related to localised immune responses at the injection site [48, 49].  524 
The Aliivibrio logei, Vibrio splendidus and Vibrio ichthyoenteri isolates were not pathogenic 525 
to ballan wrasse by i.p. injection even when very high challenge doses were administered. 526 
Aliivibrio salmonicida was the only pathogen that caused mortalities (13%) but only when 527 
very high infection dose of 5 x 10
9
 cfu/fish was administered.  528 
 529 
5- CONCLUSIONS  530 
Vaccination (by i.p.) can be used to control and potentially eliminate morbidities in ballan 531 
wrasse hatcheries and cage sites caused by aAs vapA type V and likely other vapA types (e.g. 532 
VI). The pathogenicity and virulence of Photobacterium indicum to ballan wrasse was 533 
reported for first time. Interestingly, Vibrio spp. and Aliivibrio spp. were not pathogenic by 534 
i.p. injection to the ballan wrasse population tested herein. Vaccination efficacy tests are 535 
required against Photobacterium indicum and aAs type VI, as the species is susceptible to 536 
them. Immersion vaccination strategies should be explored as the species encounters the 537 
pathogens at earlier life stages (< 25 g) and this immunisation route is desirable for juvenile 538 
ballan wrasse in the hatcheries. In addition, full characterisation of aAs isolates should be 539 
performed within the same vapA types.  540 
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 My main concern is about the vaccination procedure. It appears that the negative control 
was performed using phosphate buffered saline; while the actual vaccine was oil-
adjuvanted. Under this condition; it would be impossible to differentiate between the effect 
of the vaccine proper and that of the adjuvant. This is a concern as the protective effect of 
oil adjuvants is well-demonstrated, especially for the infection with the high dose of isolate 
TW4/14 as the difference with the control is really small. 
Thank you for your comment. In this study, due to fish and facility limited availability and 
cost, we could not test for the effect of the adjuvant alone and decided to include a PBS 
negative control only to answer the most important “industry focused” question with the 
available resources at the time. As you commented below, the specific antibody detection is 
the evidence that immunity was achieved from antigens included in the vaccine. The oil 
adjuvant effect could be explored in a future experiment.  
This issue is mitigated by the that a specific antibody response was detected, as it is likely 
that this response would play a role but this issue should be addressed by the authors. 
Ideally, by testing the protective effect of the oil adjuvant. However, I do not believe that 
this has a significant effect on the conclusions of the experiment, at least for most 
challenges where a very high RPS was detected. 
 
 In addition, more details should be given in section 2.3 regarding the preparation of the 
vaccine. How were the bacterial strain inactivated? I assume, the same quantity of each 
bacteria was added to the vaccine? 
This is a commercial product and therefore the partner company prefers not to disclose 
details related to the vaccine manufacturing. We would appreciate your understanding.  
 
 The expression "containing antigen" on line 158 is a bit confusing, while not incorrect, it 
does sound a bit like a sub-unit vaccine, while my understanding is that inactivated whole 
cells were used. 
The use of “Antigen” has been removed in the sentence. 
 
 The infection procedure on line 168 is lacking the volume and correspondence in CFU. I 
realise that the volume is presented on line 208, but I believe that the text would be easier 
to read if it was presented when the infection is described. Similarly, on line 173, the higher 
dose should be clarified. 
Authors agree and made changes accordingly. Volume and CFU are now given in line 176 
together with the infection procedure and the higher dose is now specified in line 188. 
 
Minor comments: 
 On line 87: please correct to "challenge model". – Done. 
 On line 145: please replace "confirmation" with "confirming". – Done. 
*Response to Reviewers
 On line 521: please remove the unnecessary word "was" after "challenge model" and add 
the word "the" before "Scottish isolate". – Conclusion has been changed accordingly to 
Reviewer 2 comments.  
 Highlights: I would suggest moving the last highli – Done.  
 
Reviewer 2 
1.     Abstract: Suggest delete the last two sentences (Lines 47-63). 
These two last sentences have been removed.  
2.     Line 29: Suggest report clearly on autogenous multivalent vaccines. 
Line 29 now reads ‘Autogenous (i.e. farm specific inactivated) multivalent vaccines…’.  
3.     Line 30: What is wrasse vaccine?  It is multivalent autogenous vaccines containing four strains of 
Aeromonas salmonicida and one strain of Vibrio splendidus. 
Text has been revised accordingly in lines 32 – 33. 
4.     Lines 58-114: The authors introduced bacterial pathogen, farmed salmonids, immunization, 
vaccine, ballan wrasse in the second, third and fourth paragraph of Introduction, isolates of bacteria, 
specific antibody (IgM), and RPS. Suggest describe the distribution, habitat, biology, and importance 
of ballan wrasse, and its importance in farmed salmonids like sea lice clean in salmon. Suggest report 
the research objective. 
A paragraph has been included at the start of the introduction with all the above suggestions (Lines 
59 – 73). Research objectives have also been made clearer in lines 116 – 123.  
5.     Line 59: Suggest change to farmed ballan wrasse (Labrus bergylta, ascanius). 
The scientific name has been included at the first mention of the species (Line 60). 
6.     Line 148-151: Suggest report source of water, and primary water quality parameters like total 
dissolved solids (TDS) or salinity, conductivity, hardness, and pH. 
More information has been added in line 159 however no data is available on conductivity and 
hardness of the water. 
7.     Line 159: Suggest report bacterial isolates TW3/14, TW4/14, TW187/14, TW164/15 and 
TW130/16 (Table 1). They are the strains of Aeromonas salmonicida and Vibrio splendidus. Suggest 
report source of bacterial isolate, and bacterial identification.   
This has been addressed in lines 167 – 170. 
8.     Lines 158-161: Suggest report culture of five isolates, preparation of bacterial solutions and 
concentration, and preparation of oil-based multiple autogenic vaccine and concentration. The 
statement "injectable (oil-based) autogenous vaccine" is not clear. 
The authors acknowledge your comment however given the vaccine is a commercial product, after 
discussion with the partner company, we are not allowed to disclose details related to the vaccine 
manufacturing. The word “injectable” has been removed and “emergency’ and ‘inactivated’ added in 
bracket. 
 9.     Lines 158-161: The statement "oil-based" is not clear. Can you report what kind of oil? 
Please see response above. The authors can not disclose this information. 
10.     Lines 335-337: The statements did not match with the data (Table 2). 
Data in Table 2 were corrected.  
11.     Line 448: The term "immunised fish" and "vaccinate fish" are used in the text. Suggest define 
the term. It is "vaccinated fish"?, not "immunized fish"? 
Immunised changed to vaccinated (line 456). 
12.     This is lengthy manuscript with 40 pages, and 49 references including two form the same 
groups of authors [2, 4].  
The manuscript is 29 pages long including references (without figures and table). The number of 
references in the original manuscript was <50 as recommended in the Journal guidelines. The 
authors feels that both references 2 and 4 (now 3 and 6 in the revised manuscript) are directly 
relevant to the work and would prefer to keep them in the manuscript. 
13.     Discussion is lengthy. Suggest delete the parts that are not related. 
The discussion is only 3.5 pages which is thought to be appropriate for the manuscript. The 
discussion has been rearranged to avoid back and forth to the different topics, which may have 
caused confusion and led to the reviewer to question the relevance of some sections. The authors 
believe that the flow has been improved with the relevance of all sections reaffirmed and would 
prefer to keep all parts of the discussion.  
14.     Conclusion is lengthy. Suggest delete the last sentence (Lines 535-541), and rewrite the 
conclusion. Suggest write a solid conclusion about the pathogenicity of Photobacterium indicum, 
TW3/13, TW4/14 (Aeromonmas salmonicida), and suggest report the effect of ballan wrasse that 
vaccinated with autogenous vaccine, and then later encountered bacteria. 
The authors agree with the reviewer comment. The conclusion has been shortened by half from 20 
lines to only 10 now.  
 
15.     Fig. 3: Suggest describe clearly "mock vaccinated challenged" and "vaccinated challenged", and 
"vaccinated and non-vaccinated". Suggest also report M & M clearly in the text (Lines 214-239). 
The manuscript has been revised accordingly.  
Figure 3 description has been changed to ‘Survival (%) of i.p. injected vaccinated and non – 
vaccinated (mock vaccinated) ballan wrasse challenged with atypical Aeromonas salmonicida vapA 
type V (isolate TW4/14 – A and isolate TW 3/14) at medium and high (106 and 107 cfu/fish) doses 
and high and very high doses (107 and 108 cfu/fish. Letters represents statistical significance (p < 
0.05).’ 
Changes have also been made in the M&M as follow:  
Line 224 ‘…or sterile PBS (control group / mock vaccinated).’ 
Line 236 ‘ …2 tanks containing 75 control (mock vaccinated) fish each.’ 
line 243 ‘...vaccinated and control fish (mock vaccinated) were challenged with...’ 
16.     Fig. 4: Suggest change "immunized" to "vaccinated" mock 
Done.  
17.     References: Italicize scientific names. Suggest follow the Journal guide, and check the 
references. 
References have been revised according to the Journal guidelines.  
18.     Line 564: Rewrite the reference. 
Done.  
19.     Lines 567-568, Line 577: Suggest change to Dis Aquat Org. 
Done. 
20.     Lines 573-574: Suggest change to J Fish Disease. 
Done. 
21.     Line 583: What is "University of Juvakskyla 2004"? 
Done. 
22.     Lines 586-588: Rewrite the reference. 
Done. 
23.     Lines 591-592: Rewrite the reference. 
Done. 
24.     Line 600, Line 605, Lines 610-611, Line 623, Lines 630-631, Lines 644-645, Lines 697-698 : 
Suggest change to J Fish Disease 
Done.  
25.     Line 614: What is "e1-e1"? 
This is the e-page of that the manuscript. Corrected to e1.  
26.     Line 627: Rewrite the reference. 
Done.  
27.     Lines 635-636: Suggest change to Am J Epidemiology 
Done. 
28.     Line 639: Suggest change to Fish Shellfish Immunol. 
Done. 
29.     Line 648: Suggest change to Dev Comp Immunol. 
Done. 
30.     Line 661-662: Change to Fish Shellfish Immunol. 
Done. 
31.     Line 673: Change to J Aquat Animal Health 
Done. 
32.     Line 676: Change to J Bacteriology 
Done. 
33.     Line 679: Change to J Fish Disease 
Done. 
34.     Line 683: Check "fnz074".  
It is correct; It is the e-page of the manuscript.  
35.     Lines 684-687: Check the references. 
Done. 
36.     Lines 689-690: Check abbreviation of journal ,' 
Done. 
37.     Lines 691-692: Suggest change to Fish Shellfish Immunol. 
Done. 
38.     Line 694: Suggest change to Dev Comp Immunol. 
Done. 
39.     Line 697: Suggest change to J Fish Disease 
Done. 
40.     Highlights: Highlights are lengthy and not clear. Suggest rewrite the highlights. What is 
autogenous vaccine? Not only the species Photobacterium indicum induced mortality to ballan 
wrasse. 
Highlights have been revised to make them shorter and clearer. Highlight 4 has been removed 
according to reviewer 1 comment. 
 
 
Credit author statement 
 
J. Gustavo Ramirez-Paredes (principal post-doctoral research assistant): methodology, 
experimental design, data collection, formal analyses, writing original draft  
D. Verner-Jeffreys (lead project scientist at cefas): experimental design, financial support 
and management, article review and editing  
A. Papadopoulou (PhD student in project): supported data collection, analyses (PFGE), 
writing original draft 
S. J Monaghan (post-doctoral research assistant): sample analyses for IgM responses, 
editing original draft 
L. Smith (husbandry technician at Cefas): experimental design, fish husbandry 
D. Haydon (Ridgeways): pathogens and isolates identification and characterisation by 16S 
and vapA genes prior to assignation of TW numbers, vaccine formulation, read and approved 
the final version of the MS. 
T. S. Wallis (project lead at Ridgeway): research conceptualisation, coordination and 
management 
A. Davie (Project co-PI): experimental design, supervision (PhD and PDRA), article review 
A. Adams (Project workpackage leader): experimental design, supervision (PhD and PDRA), 
article review 
 
H. Migaud (Project coordinator): project conceptualisation, financial support, management, 






Figure 1. Intraperitoneal injection vaccination of ballan wrasse with oil-adjuvanted 
autogenous vaccine. Inset: wrasse tagged with Visible Implant Elastomer tagging system. 




Figure 2.  Pulsed-filed gel electrophoresis patterns of Aeromonas salmonicida vapA type V 
isolates TW4/14, TW 187/14 and TW 3/14 restricted with SpeI enzyme (New England Labs, 
UK). From left to right, TW 3/14 (position 1), TW 4/14 (position 2) and TW 187/14 (position 
3). Molecular marker mixture of lambda DNA-Hind III fragments and lambda concatamer; 
48±5 kb (Low Range PFG Marker, New England Labs, UK). Notice the difference between 
pulsotype profiles for isolates TW 3/14 and TW 4/14 and TW 187/14 (asterisk).  
 
 
Figure 3. Survival (%) of i.p. injected vaccinated and non – vaccinated (mock vaccinated) 
ballan wrasse challenged with a Aeromonas salmonicida vapA type V (isolate TW4/14 – A 
B 
A 









 cfu/fish. Letters represents statistical significance (p < 0.05). 
 
 
Figure 4. Ballan wrasse specific antibody (IgM) response to aAs pre-vaccination (control, n= 
6 samples x 2 replicates) and after immunisation period was completed (780 DD after i.p. 




Table 1. Bacterial isolates used in this study for pathogenicity, virulence and vaccine assessment.  
 
 
Isolate ID  Bacterial species  Year of isolation  




 Aeromonas salmonicida 2014 V 
TW187/14
 v
 Aeromonas salmonicida 2014 V 
TW3/14**
 v
 Aeromonas salmonicida 2014 V  
TW164/15
 v
 Aeromonas salmonicida 2015 VI 
TW184/16* Aeromonas salmonicida 2016 VI 
TW242/16 Aliivibrio logei   2016 Isolate 1 
TW186/16 Aliivibrio logei   2016 Isolate 2 
TW322/16 Aliivibrio salmonicida 2016 Isolate 1 
TW130/16
 v
 Vibrio splendidus   2016 Isolate 1 
TW319/16 Vibrio ichthyoenteri   2016 Isolate 1 
TW138/16 Photobacterium indicum   2016 Isolate 1 
TW181/16 Photobacterium indicum   2016 Isolate 2 
(*) isolated from lumpsucker, (**) isolates used for vaccination efficacy trial, (v) isolates present 
in the commercial vaccine tested. 
























Experiment 1 6 6 aAs type V – TW4/14  1.46 9.5 x 10
7
 6 (100%) 
 
6 6 aAs type V – TW187/14  1.52 8.5 x 10
7
 6 (100%) 
 
6 6 aAs type V – TW3/14 1.49 1.0 x 10
8
 6 (100%) 
 








6 6 Vibrio ichthyoenteri TW319/16 1.48 1.0 x 10
9
 0 
       
Experiment 2 15 7 Aliivibrio salmonicida TW322/16 >2.5 5.0 x 10
9
 2 (13%) 
 








15 7 Control - 1x PBS - - 0 
 
15 8 aAs type VI – TW164/15 2 3.0 x 10
9
 15 (100%) 
       
Experiment 3  12 15 aAs type VI – TW164/15 2 3.0 x 10
9
 12 (100%) 
 
12 15 aAs type VI – TW164/15 10
-2
 3.0 x 10
7
 4 (33%) 
 
12 15 aAs type VI – TW184/16 2 1.6 x 10
9
 12 (100%) 
 
12 15 aAs type VI – TW184/16 10
-2
 1.6 x 10
7
 3 (25%) 
 
12 12 Photobacterium indicum TW138/16 1.75 3.2 x 10
9
 12 (100%) 
 
12 12 Photobacterium indicum TW138/16 10
-2
 3.2 x 10
7
 6 (50%) 
 
12 12 Photobacterium indicum TW181/16 1.89 9.0 x 10
9
 12 (100%) 
 
12 12 Photobacterium indicum TW181/16 10
-2
 9.0 x 10
7
 8 (66%)   
 




12 25 Aliivibrio logei TW242/16 10
-2








12 25 Aliivibrio logei TW186/16 10
-2
 1.8 x 10
7
 0 
       
Experiment 4   15 16 aAs type V – TW4/14 1.9 1.0 x 10
8
 15 (100%) 
 
15 16 aAs type V – TW4/14 10
-1
 1.0 x 10
7
 13 (87%) 
 
15 16 aAs type V – TW4/14 10
-2
 1.0 x 10
6
 8 (53%) 
 
15 16 aAs type V – TW4/14 10
-4




15 16 Control - 1x PBS - - 0 
 
15 19 aAs type VI – TW164/15 2 2.5 x 10
8
 1 (7%) 
 
15 19 aAs type VI – TW164/15 10
-1










15 19 aAs type VI – TW164/15 10
-4




15 19 Control - 1x PBS - n/a 0 
       
Experiment 5   15 19 aAs type V – TW4/14 1.95 dil. 10
-1
 1.0 x 10
7
 15 (100%) 
 
15 19 aAs type V – TW4/14 10
-2
 1.0 x 10
6
 8 (53%) 
 
15 19 aAs type V – TW4/14 10
-3
 1.0 x 10
5
 7 (47%) 
 
15 19 aAs type V – TW4/14 10
-4
 1.0 x 10
4
 1 (7%) 
  15 19 aAs type V – TW4/14 10
-5




Table 3. Experimental design of the vaccine efficacy trial and relative percent 
survival (RPS) results. 
 
 
Species and Isolate Tank and (n) Dose type cfu/fish RPS (%) 
aAs vapA type V (TW4/14) 
T03-10; 90 fish 
(45v +45c) 
Medium 1.0 x 10
6
 95 
aAs vapA type V (TW4/14) 
T03-09; 90 fish 
(45v +45c) 
High 1.0 x 10
7
 91 
aAs vapA type V (TW3/14) 
T03-08; 90 fish 
(45v +45c) 
High 1.0 x 10
7
 79 
aAs vapA type V (TW3/14) 
T03-07; 90 fish 
(45v +45c) 
Very high 1.0 x 10
8
 20 
V= vaccinated; C= control 




Table 4. Lethal dose 50% (LD50) of 6 bacterial species used in the trials by day 8 post infection. 
  
 
Bacterial species Isolate LD50 (cfu/fish) 
Atypical Aeromonas salmonicida type V  TW4/14* 2.0 x 10
5
 
Atypical Aeromonas salmonicida type V  TW4/14 2.8 x 10
6
 
Atypical Aeromonas salmonicida type V  TW4/14** 6.1 x 10
6
 
Atypical Aeromonas salmonicida type V   TW3/14** 1.6 x 10
7
 
Photobacterium indicum TW181/16 <3.2 x 10
7
 
Photobacterium indicum TW138/16 1.3 x 10
8
 
Atypical Aeromonas salmonicida type VI  TW184/16 3.4 x 10
8
 
Atypical Aeromonas salmonicida type VI  TW164/15 5.3 x 10
8
 
Aliivibrio logei TW242/16 >1.5 x 10
9
 
Aliivibrio logei TW186/16 >1.8 x 10
9
 
Vibrio splendidus TW130/16 >3.0 x 10
9
 
Aliivibrio salmonicida TW322/16 >5.0 x 10
9
 
Vibrio ichthyoenteri TW319/16 >8.0 x 10
9
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